Company intelligence / Profile preview

Complexo Hospitalar Ulbra e Oncovita

Paris, France

Ownership: Private
Development stage: Commercial

Overview

Preclinical data show that the lead candidate—a genetically modified measles virus—demonstrates activity against several cancers. The company has secured €4.5 million in funding under France’s “Innovations in Biotherapies and Bioproduction” program to advance its pipeline toward clinical trials. Initial proof-of-concept work with Unither focuses on pediatric vaccine delivery using novel packaging formats.

Therapeutic areas: OncologyInfectious Diseases
Modalities: Virus-derived vaccine therapyOncolytic virus therapyVaccineBiologic
Industry: Biotech

Partnerships

Institut Pasteur (exclusive worldwide license for immuno-oncolytic measles platform)Unither Pharmaceuticals (vaccine formulation/packaging partnership)

Beyond the preview

Go deeper on Complexo Hospitalar Ulbra e Oncovita.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Complexo Hospitalar Ulbra e Oncovita.

Explore the full profile